SCHEMBL12988312

SCHEMBL12988312

CC(C)(C)OC(=O)N1CCC(C(=O)O)(c2ccc(Br)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.53
▸ ALOX15 P16050 1/20 0.53
▸ ATM Q13315 1/20 0.53
▸ RORC P51449 3/20 0.51
▸ TET3 O43151 4/20 0.46
▸ KMT2A Q03164 4/20 0.46
▸ FBXL19 Q6PCT2 4/20 0.46
▸ CXXC5 Q7LFL8 4/20 0.46
▸ KDM2B Q8NHM5 4/20 0.46
▸ CXXC4 Q9H2H0 4/20 0.46
▸ KDM2A Q9Y2K7 4/20 0.46
▸ TET1 Q8NFU7 3/20 0.46
▸ FPR3 P25089 1/20 0.44
▸ FPR2 P25090 1/20 0.44
▸ GPR119 Q8TDV5 2/20 0.43
▸ ESRRB O95718 1/20 0.42
▸ ESR1 P03372 1/20 0.42
▸ ESRRA P11474 1/20 0.42
▸ ESRRG P62508 1/20 0.42
▸ JAK2 O60674 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4629887 0.88 TSHR (0.49) TSHRALOX15ATMRORCFPR3
SCHEMBL972474 0.88 TSHR (0.65) TSHRALOX15ATMTET3KMT2A
SCHEMBL26930774 0.88 TSHR (0.54) TSHRALOX15ATMRORCFPR3
SCHEMBL26930433 0.87 TSHR (0.51) TSHRALOX15ATMRORCFPR3
SCHEMBL28028621 0.87 TSHR (0.56) TSHRALOX15ATMRORCTET3
SCHEMBL396197 0.87 TSHR (0.53) TSHRALOX15ATMRORCTET3
SCHEMBL654813 0.87 KMT2A (0.59) TSHRALOX15ATMTET3KMT2A
SCHEMBL28953849 0.86 TET3 (0.64) TSHRALOX15ATMTET3KMT2A
SCHEMBL31694033 0.85 TSHR (0.52) TSHRALOX15ATMRORCTET3
SCHEMBL28029029 0.85 TSHR (0.52) TSHRALOX15ATMRORCTET3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361230-A1 LATS Inhibitors and Uses Thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2025-11-27 — — US disclosed
EP-4536657-A1 LATS INHIBITORS AND USES THEREOF The USA, as represented by The Secretary, Department of Health and Human Services (US) 2025-04-16 — — EP disclosed
WO-2023239727-A1 LATS INHIBITORS AND USES THEREOF THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2023-12-14 — — WO disclosed
WO-2023239727-A1 LATS INHIBITORS AND USES THEREOF THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2023-12-14 — — WO disclosed
CN-104876934-B A kind of nitrogen heterocyclic ring phenylpiperidine compound and preparation method and application 山东大学 2017-08-11 — — CN disclosed
CN-104876934-A Nitrogen-containing heterocyclic phenyl piperidine compound as well as preparation method and application thereof UNIV SHANDONG 2015-09-02 — — CN disclosed
WO-2012138648-A1 COMPOSITIONS AND METHODS FOR MODULATING LPA RECEPTORS IRM LLC (BM) 2012-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250361230-A1 LATS Inhibitors and Uses Thereof LATS2, LATS1, AKT1S1 TSHR 2427/4885ALOX15 1115/4885ATM 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback